The estimated Net Worth of Bahram Valamehr is at least $5.32 Milion dollars as of 9 January 2024. Bahram Valamehr owns over 11,271 units of Fate Therapeutics Inc stock worth over $613,308 and over the last 6 years he sold FATE stock worth over $1,883,794. In addition, he makes $2,818,590 as Chief Development Officer at Fate Therapeutics Inc.
Bahram has made over 18 trades of the Fate Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 11,271 units of FATE stock worth $49,367 on 9 January 2024.
The largest trade he's ever made was exercising 25,000 units of Fate Therapeutics Inc stock on 14 March 2022 worth over $68,250. On average, Bahram trades about 10,213 units every 62 days since 2019. As of 9 January 2024 he still owns at least 158,069 units of Fate Therapeutics Inc stock.
You can see the complete history of Bahram Valamehr stock trades at the bottom of the page.
Dr. Bahram Valamehr Ph.D. is Chief Development Officer of the company. From January 2010 to August 2018, Dr. Valamehr served in roles of increasing responsibility with the Company, most recently from December 2016 to August 2018 as our Vice President of Cancer Immunotherapy where he led the R&D activities associated with the Company’s immuno-oncology franchise. Prior to that, Dr. Valamehr played key scientific roles at Amgen, the Center for Cell Control (a NIH Nanomedicine Development Center), and the Broad Stem Cell Research Center developing novel methods to control pluripotency, to modulate stem cell fate including hematopoiesis and to better understand cellular signaling pathways associated with cancer. Dr. Valamehr received his Ph.D. in molecular and medical pharmacology from the University of California, Los Angeles, his M.B.A. from Pepperdine University, and his B.S. in biochemistry from the University of California, Los Angeles.
As the Chief Development Officer of Fate Therapeutics Inc, the total compensation of Bahram Valamehr at Fate Therapeutics Inc is $2,818,590. There are 1 executives at Fate Therapeutics Inc getting paid more, with John Wolchko having the highest compensation of $10,721,000.
Bahram Valamehr is 43, he's been the Chief Development Officer of Fate Therapeutics Inc since 2018. There are 15 older and 1 younger executives at Fate Therapeutics Inc. The oldest executive at Fate Therapeutics Inc is William Rastetter, 72, who is the Independent Chairman of the Board.
Bahram's mailing address filed with the SEC is C/O FATE THERAPEUTICS, INC., 12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA, 92131.
Over the last 11 years, insiders at Fate Therapeutics Inc have traded over $48,476,146 worth of Fate Therapeutics Inc stock and bought 11,483,795 units worth $162,421,037 . The most active insiders traders include Group, Llc Green Jeremy Red..., Associates V Lpvenrock Part... oraz Amir Nashat. On average, Fate Therapeutics Inc executives and independent directors trade stock every 26 days with the average trade being worth of $384,496. The most recent stock trade was executed by Yuan Xu on 6 August 2024, trading 633 units of FATE stock currently worth $2,678.
fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate Therapeutics Inc executives and other stock owners filed with the SEC include: